Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma

<div>The K-M plot showing the different OS in subgroups. (a) Different OS outcomes in high- and low-expression groups of FCRLs. (b) Different OS outcomes in sex, age, stage, and Breslow’s depth subgroups.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma 